Durin Life Sciences, Inc. — Form D/A
Durin Life Sciences, Inc. of STRATFORD, NJ, a company, filed a Form D amendment with the SEC on 2023-01-09. The offering totals $5.5M, of which $4.6M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-01-09
- Form: D/A
- Accession: 0001797306-23-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $5.5M
- Amount sold: $4.6M
- Remaining: $946K
- Investors: 2
- Date of first sale: 2021-03-16
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-393159
Issuer
- Name: Durin Life Sciences, Inc.
- CIK: 0001797306
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 2 MEDICAL CENTER DR #213A, STRATFORD, NJ, 08084
- Phone: 877-387-4657
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Rene A Chaze | Director | Mullica Hill, NJ |
| Robert A Nagele | Director | Mullica Hill, NJ |
| Benjamin A Belinka, Jr. | Executive Officer | Mullica Hill, NJ |
| Maribeth Bluyus | Executive Officer | Stratford, NJ |
| Robert Nagele | Director | Stratford, NJ |
| Rene Chaze | Director | Stratford, NJ |
| Mert Sahin | Executive Officer | Stratford, NJ |
Other filings by this issuer (5)
More